Halifax, CANADA: January 4, 2012 - Immunovaccine Inc. (TSX-V: IMV) today announced the first patient has been vaccinated with DPX-Survivac, a therapeutic cancer vaccine. The goal of the Phase I clinical trial is to establish the safety and immune activity of DPX-Survivac in patients with ovarian cancer.
The DPX-Survivac Phase I and II clinical trials have been cleared by both the U.S. FDA and Health Canada. DPX-Survivac is a survivin-targeting vaccine formulated in the DepoVax™ platform, a patented vaccine delivery and method that is expected to enhance the immunogenicity of the survivin antigen used in DPX-Survivac. The survivin antigen contained in the vaccine is a broadly expressed, tumor-associated antigen shown to sustain the survival of cancer cells. In combination with the DepoVax platform, it is expected to stimulate the immune system to destroy cancer cells expressing survivin and delay cancer recurrence.
DPX-Survivac will be administered to patients after debulking surgery and chemotherapy treatments. Vaccinated patients will also receive an immune modulating drug to further enhance the activity of the vaccine.
"We believe this is the right vaccine being administered at the right time," commented Dr. Mansour, Chief Science and Operating Officer. "Applying our DepoVax enhanced vaccine after surgery and chemotherapy is when therapeutic cancer vaccines are expected to be most effective."
About the Clinical Trial
The Phase I portion of the DPX-Survivac clinical trial is
an open-label, dose-ranging study, enrolling up to 15
patients with stage IIc-IV ovarian cancer. Preliminary
safety results, established from the first three patients,
are expected in Q1/Q2 2012. Completion of patient
enrollment in the Phase I study, along with a broader
assessment of the vaccine's safety and immune activity is
estimated to be completed by Q4 2012.
Following the completion of the Phase I clinical trial, Immunovaccine is cleared to initiate, without any further application to the U.S. FDA or Health Canada, a randomized, double-blinded, placebo-controlled Phase II clinical trial, with a selected vaccine dose. The Phase II trial will assess the clinical benefit of DPX-Survivac in patients with advanced ovarian cancer. For more details visit .
About DPX-Survivac
DPX-Survivac consists of survivin-based peptide antigens
formulated in the DepoVax™ adjuvanting platform. Survivin
has been recognized by the National Cancer Institute (NCI)
as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity.
Survivin is broadly over-expressed in multiple cancer types
in addition to ovarian cancer, including breast, colon and
lung cancers. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated
angiogenesis, and promoting resistance to various
anti-cancer therapies. Survivin is also a prognostic factor
for many cancers and it is found in a higher percentage of
tumors than other TAA's.
The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively and specifically search for and destroy tumor cells. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.
Several investigator-driven clinical trials have shown that a survivin-based vaccine is capable of generating an immune response and providing a potential therapeutic benefit. In preparation for human trials with DPX-Survivac, Immunovaccine was able to show that its DepoVax platform raises a significantly higher survivin-specific immune response in animal models compared to the vaccine formulation previously used in clinical trials.
Proof-of-Concept in Ovarian Cancer
DPX-Survivac is a therapeutic vaccine applicable to
multiple cancers, such as breast, colon and lung cancers,
as well as hematological malignancies and melanoma.
Immunovaccine has chosen to conduct clinical
proof-of-concept for DPX-Survivac in ovarian cancer because
of the limited treatment options and the presence of
survivin in up to 90% of ovarian cancers. There is
also the ability to apply the DPX-Survivac vaccine in a
patient population with initial minimal residual disease,
post the current standard of care, but known to have a high
rate of recurrence within an average of 18 months.
About Ovarian Cancer
Ovarian cancer has the highest mortality of all cancers of
the female reproductive system. This reflects, in
part, a lack of early symptoms and lack of ovarian cancer
screening tests. Ovarian cancer is often diagnosed at
an advanced stage (III and IV), after the cancer has spread
beyond the ovary. It is estimated that approximately
$2.2 billion is spent in the U.S. each year on treatment of
ovarian cancer.
About Immunovaccine
Immunovaccine Inc. develops vaccines formulated in its
vaccine enhancement platform for cancer and infectious
disease. The Company's DepoVax™ platform is a patented
lipid delivery system presenting antigens plus adjuvant to
the immune system in a unique depot. This is expected to
allow for controlled uptake of vaccine ingredients and
enhanced activation of immune cells resulting in more
effective immune responses. Immunovaccine has taken its
platform technology and proprietary cancer vaccine,
DPX-0907, into Phase I human trials and has demonstrated
its safety and immune activity potential. The Company is
also capitalizing on the broad potential of its delivery
platform by creating new DepoVax-based vaccines through
multiple development collaborations. In addition to the
Company's human health vaccine strategy, it continues to
capture value from animal health vaccine applications.
Pfizer Animal Health has licensed the Company's delivery
technology platform to develop vaccines for
livestock. Connect at or
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
-30-
Contact:
Dr. Marc Mansour, CSO, COO, Immunovaccine Inc.
T: (902) 492-1819 E: info@imvaccine.com
OR
Jennifer Cameron, Director Communications, Immunovaccine
Inc.
T: (902) 492-1819 E: jayotte@imvaccine.com
Media :
Andrew Mielach, Account Director, Tiberend Strategic
Advisors, Inc.
T : (212) 827-0020 E : amielach@tiberend.com
distribué par | Ce noodl a été diffusé par Immunovaccine Inc. et initialement mise en ligne sur le site http://www.imvaccine.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-04 14:49:20 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |